First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
https://doi.org/10.14412/1995-4484-2008-416
Abstract
Introduction. Adalimumab (Humira) is a monoclonal anti-TNFa antibody fully identical to human antibodies, a member of group of TNFa blockers which are now the main biological drugs for the treatment of rheumatoid arthritis (RA). Till recently adalimumab was little known in Russia. Material and methods. 24 pts (2 male and 22 female) were included in an open 24-week clinical study of adalimumab in active RA. Mean duration of the disease was 6,4 years. 5 pts had early RA. In all pts DAS28 was higher than 5,1. All pts earlier received main traditional DMARDs (methotrexate, leflunomide, sulfasalazine) and steroids without significant improvement. All pts were treated on an outpatient basis. Adalimumab 40 mg was injected subcutaneously with 2 weeks intervals during 24 weeks. Results. 22 from 24 pts (91,7%) completed full course of treatment with adalimumab. All outcome measures (pt self assessment on VAS, DAS28,HAQ, CRP) showed fast and sustained improvement. Good effect according to EULAR criteria was achieved in 8 (33,4%), moderate — in 14 (58,3%) pts and 2 pts (8,3%) did not respond to the treatment. Effect did not depend on age, previous treatment, comorbid diseases and disease duration. During follow up period serious adverse events and tuberculosis did not appear in this group of pts. Conclusion. Adalimumab is a highly effective biological drug from the group of TNFa blockers which is particularly useful for the treatment of RA resistant to conventional therapy on an outpatient basis.
References
1. <div><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в XXI век. Клин, мед., 2005, 6, 8-12</p><p>Лечение ревматоидного артрита. Клинические рекомендации. Под ред. Е.Л.Насонова. ООО «Алмаз», 2006, 118с.</p><p>Насонов Е. Л. Перспективы применения полностью человеческих моноклональных антител к фактору некроза опухоли (адалимумаба) при ревматоидном артрите. Клин. Фармакол. Терапия, 2007, 1, 71 - 74</p><p>Каратеев Д.Е. Современная медикаментозная терапия ревматоидного артрита. Леч. Врач, 2007, 2, 40-46</p><p>Furst D.E. Breedveld F.C., Kalden J.R. et al., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann. Rlieum. Dis. 2007, 666 Suppl 3, Ш2-22</p><p>Weinblatt M.E., Keystone E.C., FurstD.E., etal. Long term safety, efficacy and remission with adalimumab (Humira) and methotrexate combination therapy in rheumatoid arthritis (RA) 7-year analysis. Abstr. 9th Annual EULAR 2008 meeting, Paris, AB0343</p><p>Alonso-RuizA., Pijoan J.I., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet. Disord., 2008, 17; 9(1), 52</p><p>Kievit W., Adang EM., Frartsen J. et al. The effectiveness and medication costs of three antitumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis., 2008, 67(9), 1229-1234</p><p>Каратеев Д.Е., Олюнин Ю.А., О классификации ревматоидного артрита. Научно-практич. ревматол., 2008, 1, 5-16</p><p>Ревматические болезни. Национальное руководство. Под ред. Е.Л.Насонова. Москва, «ГЭОТАР- Медиа», 2008.</p><p>Амирджанова В.Н. Шкалы боли и HAQ в оценке пациента с ревматоидным артритом. Научно- практич. ревматол., 2006, 2, 60-65</p><p>Weinblatt М.Е., Keystone Е.С., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr. Rheum. 2003, 48, 35-45</p></div><br />
Review
For citations:
Luchichina E.L., Karateev D.E., Nasonov E.L. First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study. Rheumatology Science and Practice. 2008;46(5):59-63. (In Russ.) https://doi.org/10.14412/1995-4484-2008-416
Views:
1108
Email this article 